布地奈德联合不同药物雾化吸入疗法在儿童哮喘急性发作期的疗效评价

Efficacy Evaluation of Budesonide Combined with Different Drugs Nebulized Inhalation Therapy in Acute Attack of Childhood Asthma

目的评价布地奈德联合不同药物雾化吸入疗法在儿童哮喘急性发作期的疗效。方法随机选取该院在2018年6月—2020年6月期间收治的100例哮喘急性发作期患儿为研究对象,随机分组,分为对照组和研究组,每组50例,其中对照组的患儿使用布地奈德雾化吸入治疗,研究组的患儿给予布地奈德联合丙酸倍氯米松雾化吸入的治疗,比较两组患儿哮喘缓解时间和咳嗽缓解时间,护理前后两组患儿的肺功能相关检测指标,包括用力肺活量(FVC)、第1秒用力呼气容积(FEV1)以及最大呼气至50%时呼气的流量值(MEF50),同时比较两组患儿的炎性因子水平,包括白细胞介素-4(IL-4)、白细胞介素-5(IL-5)以及干扰素-γ(IFN-γ)。结果研究组患儿的哮喘和咳嗽缓解时间分别为(3.32±0.95)d和(4.02±1.23)d,对照组为(4.12±0.96)d和(5.16±1.25)d,研究组明显优于对照组,差异有统计学意义(t=4.188、4.597,P<0.05);治疗前两组患儿的FVC、FEV1以及MEF50水平差异无统计学意义(P>0.05),而治疗后研究组FEV1(1.50±0.42)L、MEF50(73.94±3.38)%与对照组比较,差异有统计学意义(t=2.606、12.406,P<0.05),FVC(2.39±0.75)L与对照组比较,差异无统计学意义(t=0.405,P>0.05);研究组治疗后的IL-4(24.28±3.64)ng/L、IL-5(39.87±4.03)ng/L、IFN-γ(18.83±3.38)ng/L与对照组比较,差异有统计学意义(t=9.894、6.719、6.134,P<0.05)。结论在治疗小儿急性发作期的哮喘时,使用布地奈德联合丙酸倍氯米松雾化吸入疗法具有较高的临床价值,能够在短时间内帮助患儿缓解哮喘及咳嗽症状,且使炎性因子水平得以恢复,因此在实际临床应用中,可以综合选择二者药物的联合使用。

Objective To evaluate the efficacy of budesonide combined with different drugs inhalation inhalation therapy in the acute attack of childhood asthma.Methods 100 children with acute asthma attack admitted in the hospital from June 2018 to June 2020 were conveniently selected as the research objects.They were randomly divided into control group andstudy group,each with 50 cases,among which the control group patients were treated with budesonide nebulized inhalation,and the study group of children were treated with budesonide combined with beclomethasone propionate nebulized inhalation.The asthma remission time and cough remission time of the two groups were compared.The two groups of children before and after nursing of the pulmonary function related testing indicators,including forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),and expiratory flow value(MEF50)when the maximum expiration reaches 50%.At the same time,the inflammation of the two groups of children was compared,including interleukin-4(IL-4),interleukin-5(IL-5)and interferon-γ(IFN-γ).Results The asthma and cough relief time of the children in the study group was(3.32±0.95)d and(4.02±1.23)d,respectively,and the control group was(4.12±0.96)d and(5.16±1.25)d.The study group was significantly better than the control group,the difference was statistically significant(t=4.188,4.597,P<0.05);there was no statistically significant difference in the levels of FVC,FEV1 and MEF50 between the two groups of children before treatment(P>0.05),while FEV1(1.50±0.42)L and MEF50(73.94±3.38)%in the study group after treatment compared with the control group,the difference was statistically significant(t=2.606,12.406,P<0.05),FVC(2.39±0.75)L had no statistically significant difference compared with the control group(t=0.405,P>0.05);IL-after treatment in thestudy group 4(24.28±3.64)ng/L,IL-5(39.87±4.03)ng/L,IFN-γ(18.83±3.38)ng/L were significantly different from the control group,the difference was statistically significant(t=9.894,6.719,6.134,P<0.05).Conclusion In the treatment of children with acute asthma,the use of budesonide combined with beclomethasone propionate nebulized inhalation therapy has high clinical value,which can help children relieve asthma and cough symptoms in a short period of time,and make inflammation.The factor level is restored,so in actual clinical application,the combined use of the two drugs can be comprehensively selected.